Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death

BACKGROUND: CRM1 enrichment has been shown to be indicative of invasive as well as chemoresistant tumors. On the other hand, TRAIL, a powerful and specific anti-tumoral agent, has yet to be used effectively to treat gynecological tumors in patients. In the present study, we examined if CRM1, a nucle...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabi, François, Adam, Pascal, Vincent, Keven, Demontigny, Françis, Parent, Sophie, Joncas, France-Hélène, Asselin, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033231/
https://www.ncbi.nlm.nih.gov/pubmed/29973205
http://dx.doi.org/10.1186/s12964-018-0252-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033231/
https://www.ncbi.nlm.nih.gov/pubmed/29973205
http://dx.doi.org/10.1186/s12964-018-0252-z

Ejemplares similares